Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 3, Pages 717
Publisher
MDPI AG
Online
2020-03-19
DOI
10.3390/cells9030717
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
- (2020) Piers Blombery et al. BLOOD
- AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia
- (2020) Xue Yi et al. CLINICAL CANCER RESEARCH
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
- (2019) Benoît Tessoulin et al. Frontiers in Oncology
- Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
- (2019) Shannon M. Matulis et al. LEUKEMIA
- Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
- (2019) Andrew D. Zelenetz et al. BLOOD
- BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
- (2019) Xiaohong Zhao et al. CANCER CELL
- Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- (2019) Dana Prukova et al. CLINICAL CANCER RESEARCH
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
- (2019) Eugen Tausch et al. HAEMATOLOGICA
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
- (2019) Esperanza M Algarín et al. HAEMATOLOGICA
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
- (2019) Romain Guièze et al. CANCER CELL
- Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL
- (2019) Preetesh Jain et al. BLOOD
- Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- (2019) Philippe Moreau et al. BLOOD
- Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
- (2019) Victoria M. Smith et al. HAEMATOLOGICA
- Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
- (2019) Michael A. Dengler et al. ONCOGENE
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statins enhance efficacy of venetoclax in blood cancers
- (2018) J. Scott Lee et al. Science Translational Medicine
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
- (2018) Patricia Gomez-Bougie et al. BLOOD
- Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in haematological malignancies
- (2018) Aoula Al-Zebeeby et al. HAEMATOLOGICA
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- (2018) Rishu Agarwal et al. NATURE MEDICINE
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment
- (2017) Antonin Papin et al. LEUKEMIA & LYMPHOMA
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
- (2016) D. Chiron et al. BLOOD
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
- (2016) Sina Oppermann et al. BLOOD
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
- (2016) M. A. Anderson et al. BLOOD
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
- (2016) J.-N. Gong et al. BLOOD
- BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma
- (2016) Christelle Dousset et al. BRITISH JOURNAL OF HAEMATOLOGY
- Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling
- (2016) Victor Peperzak et al. CELL DEATH AND DIFFERENTIATION
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
- (2016) Y Li et al. ONCOGENE
- Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
- (2016) Juraj Bodo et al. Oncotarget
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
- (2015) R. Thijssen et al. HAEMATOLOGICA
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
- (2015) C Touzeau et al. LEUKEMIA
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
- (2015) David Chiron et al. Oncotarget
- Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
- (2015) R. Thijssen et al. HAEMATOLOGICA
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
- (2013) R. L. Thomas et al. GENES & DEVELOPMENT
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
- (2011) T. N. Chonghaile et al. SCIENCE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now